Cardiol Therapeutics Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cardiol Therapeutics Inc., a foreign private issuer, on September 7, 2021. The report covers the month of September 2021 and discloses a corporate governance update regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The material change disclosed in this filing is the appointment of Michael J. Willner to the Company's Board of Directors, as detailed in the accompanying news release (Exhibit 99.1).
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, future outlook, management commentary on operations, specific risks, contingencies, or unusual items beyond the board appointment.
Key Facts for Investor Verification
- Michael J. Willner has been appointed to the Board of Directors.
- The filing was signed by Chris Waddick, Chief Financial Officer, on September 7, 2021.
- The company is headquartered in Oakville, Ontario, Canada.
- No financial performance data is included in this specific document.